AbbVie FY 2023: revenue $54.3B, down 6%; diluted EPS $2.72

Key figures from this report

These are the numbers AbbVie reported for the year ended Dec 31, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

1. Revenue$54.3B−6% from $58.1B in FY 202210-K income statement, on EDGAR
2. Net income$4.9B−59% from $11.8B in FY 202210-K income statement, on EDGAR
3. Diluted EPS$2.72−59% from $6.63 in FY 202210-K income statement, on EDGAR
4. Cash and cash equivalents$12.8B+39% from $9.2B in FY 2022Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
5. Cash from operations$22.8B−8% from $24.9B in FY 202210-K cash flow statement, on EDGAR

Every year in the financial tables